Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This prospective, single-arm study is conducted to investigate the safety and efficacy of
Sintilimab combined with hypofractionated radiotherapy in patients with microsatellite
instability-high (MSI-H)/ DNA mismatch repair-deficient (dMMR) non-metastatic rectal cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
West China Hospital
Collaborators:
Chengdu Third People's Hospital First Affiliated Hospital of Chongqing Medical University Sichuan Cancer Hospital and Research Institute The Affiliated Hospital Of Southwest Medical University Yunnan Cancer Hospital